7bg0: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Fusion of MBP and the backbone of the long-acting amylin analog AM833.== | ==Fusion of MBP and the backbone of the long-acting amylin analog AM833.== | ||
<StructureSection load='7bg0' size='340' side='right'caption='[[7bg0]]' scene=''> | <StructureSection load='7bg0' size='340' side='right'caption='[[7bg0]], [[Resolution|resolution]] 2.89Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7BG0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7BG0 FirstGlance]. <br> | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7BG0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7BG0 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7bg0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7bg0 OCA], [https://pdbe.org/7bg0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7bg0 RCSB], [https://www.ebi.ac.uk/pdbsum/7bg0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7bg0 ProSAT]</span></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.89Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GLC:ALPHA-D-GLUCOSE'>GLC</scene>, <scene name='pdbligand=PRD_900001:alpha-maltose'>PRD_900001</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7bg0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7bg0 OCA], [https://pdbe.org/7bg0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7bg0 RCSB], [https://www.ebi.ac.uk/pdbsum/7bg0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7bg0 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acting amylin analogue cagrilintide (23) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide. | |||
Development of Cagrilintide, a Long-Acting Amylin Analogue.,Kruse T, Hansen JL, Dahl K, Schaffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K J Med Chem. 2021 Jul 21. doi: 10.1021/acs.jmedchem.1c00565. PMID:34288673<ref>PMID:34288673</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7bg0" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Maltose-binding protein 3D structures|Maltose-binding protein 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Johansson E]] | [[Category: Johansson E]] | ||
Latest revision as of 12:21, 9 October 2024
Fusion of MBP and the backbone of the long-acting amylin analog AM833.Fusion of MBP and the backbone of the long-acting amylin analog AM833.
Structural highlights
Publication Abstract from PubMedA hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acting amylin analogue cagrilintide (23) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide. Development of Cagrilintide, a Long-Acting Amylin Analogue.,Kruse T, Hansen JL, Dahl K, Schaffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K J Med Chem. 2021 Jul 21. doi: 10.1021/acs.jmedchem.1c00565. PMID:34288673[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||